ATE148632T1 - Synergistische therapeutische zusammensetzungen und verfahren - Google Patents

Synergistische therapeutische zusammensetzungen und verfahren

Info

Publication number
ATE148632T1
ATE148632T1 AT91909382T AT91909382T ATE148632T1 AT E148632 T1 ATE148632 T1 AT E148632T1 AT 91909382 T AT91909382 T AT 91909382T AT 91909382 T AT91909382 T AT 91909382T AT E148632 T1 ATE148632 T1 AT E148632T1
Authority
AT
Austria
Prior art keywords
methods
therapeutic compositions
synergistic therapeutic
synergistic
compositions
Prior art date
Application number
AT91909382T
Other languages
English (en)
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE148632(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE148632T1 publication Critical patent/ATE148632T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91909382T 1990-05-11 1991-04-22 Synergistische therapeutische zusammensetzungen und verfahren ATE148632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11

Publications (1)

Publication Number Publication Date
ATE148632T1 true ATE148632T1 (de) 1997-02-15

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909382T ATE148632T1 (de) 1990-05-11 1991-04-22 Synergistische therapeutische zusammensetzungen und verfahren

Country Status (34)

Country Link
US (2) US6716875B1 (de)
EP (1) EP0527879B1 (de)
JP (2) JPH0729938B2 (de)
KR (1) KR970005839B1 (de)
CN (7) CN100358578C (de)
AP (1) AP240A (de)
AT (1) ATE148632T1 (de)
AU (1) AU653724B2 (de)
BG (1) BG61831B1 (de)
BR (1) BR9106438A (de)
CA (1) CA2081564C (de)
DE (1) DE69124598T2 (de)
DK (1) DK0527879T3 (de)
EG (1) EG19648A (de)
ES (1) ES2097208T3 (de)
GR (1) GR3022997T3 (de)
GT (1) GT199100032A (de)
HK (1) HK1094148A1 (de)
HU (1) HU227346B1 (de)
IE (1) IE911592A1 (de)
IL (1) IL98055A (de)
IS (1) IS2042B (de)
MA (1) MA22150A1 (de)
MY (1) MY114347A (de)
NO (1) NO924321L (de)
NZ (1) NZ238118A (de)
PE (1) PE30891A1 (de)
PT (1) PT97615B (de)
RO (1) RO115786B1 (de)
RU (1) RU2147875C1 (de)
TW (1) TW203553B (de)
WO (1) WO1991017771A1 (de)
YU (1) YU49094B (de)
ZA (1) ZA913539B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227346B1 (en) * 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
CA2214143A1 (en) * 1995-04-07 1996-10-10 Marc De Gasparo Combination compositions containing benazepril or benazeprilat and valsartan
EP0835106A4 (de) * 1995-06-30 1998-09-30 Merck & Co Inc Verfahren zur behandlung von nierenkrankheiten unter verwendung eines ace inhibitors und eines aii antagonisten
SI0914158T2 (sl) * 1996-04-05 2006-04-30 Takeda Chemical Industries Ltd Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1997049392A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
ES2184340T3 (es) * 1997-12-23 2003-04-01 Warner Lambert Co Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
KR20070101843A (ko) * 2004-10-08 2007-10-17 노파르티스 아게 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
ES2570374T3 (es) 2007-03-29 2016-05-18 Progenics Pharm Inc Antagonistas del receptor opioide periférico y usos de los mismos
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
HU227346B1 (en) * 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition

Also Published As

Publication number Publication date
PT97615A (pt) 1992-03-31
IL98055A0 (en) 1992-06-21
AU7859191A (en) 1991-12-10
EP0527879A1 (de) 1993-02-24
YU49094B (sh) 2003-12-31
JP2635291B2 (ja) 1997-07-30
NO924321L (no) 1993-01-08
GR3022997T3 (en) 1997-07-30
IS3703A7 (is) 1991-11-12
HU9203522D0 (en) 1993-01-28
KR970005839B1 (ko) 1997-04-21
PE30891A1 (es) 1991-11-27
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
JPH0748280A (ja) 1995-02-21
EG19648A (en) 1995-09-30
CN1502370A (zh) 2004-06-09
HK1094148A1 (en) 2007-03-23
RO115786B1 (ro) 2000-06-30
NZ238118A (en) 1997-06-24
JPH0729938B2 (ja) 1995-04-05
US6900234B1 (en) 2005-05-31
GT199100032A (es) 1992-10-31
WO1991017771A1 (en) 1991-11-28
AP240A (en) 1993-02-18
ZA913539B (en) 1992-12-30
US6716875B1 (en) 2004-04-06
AU653724B2 (en) 1994-10-13
BG61831B1 (bg) 1998-07-31
RU2147875C1 (ru) 2000-04-27
IE911592A1 (en) 1991-11-20
IL98055A (en) 1996-10-31
CN1879884A (zh) 2006-12-20
TW203553B (de) 1993-04-11
CN1065140C (zh) 2001-05-02
CN1915428A (zh) 2007-02-21
CN101156949A (zh) 2008-04-09
BR9106438A (pt) 1993-05-18
CA2081564A1 (en) 1991-11-12
AP9100258A0 (en) 1991-07-31
CN1056426A (zh) 1991-11-27
DK0527879T3 (da) 1997-07-14
ES2097208T3 (es) 1997-04-01
MY114347A (en) 2002-10-31
DE69124598T2 (de) 1997-05-28
MA22150A1 (fr) 1991-12-31
HU227346B1 (en) 2011-04-28
IS2042B (is) 2005-09-15
CN1824315B (zh) 2011-01-12
EP0527879B1 (de) 1997-02-05
NO924321D0 (no) 1992-11-10
CN100358578C (zh) 2008-01-02
DE69124598D1 (de) 1997-03-20
HUT62804A (en) 1993-06-28
YU81991A (sh) 1994-06-24
PT97615B (pt) 1998-08-31
CN1307901A (zh) 2001-08-15
JPH05505618A (ja) 1993-08-19

Similar Documents

Publication Publication Date Title
ATE148632T1 (de) Synergistische therapeutische zusammensetzungen und verfahren
NO941929L (no) Tokotrienoler og tokotrienol-lignende sammensetninger og fremgangsmåter for deres anvendelse
DE69230954D1 (de) Modulare Schnittstelle und Verfahren hierfür
DE69324942D1 (de) Strahlungsempfindliche Zusammensetzungen und Verfahren
DE68918943T2 (de) Gewebeentzusammensetzung und verfahren.
DE69211276T2 (de) Verfahren und Schleifvorrichtung
DE68928033D1 (de) Stereosynthesizer und entsprechendes verfahren
BR1100824A (pt) Composto e composição farmacêutica
DE69212502D1 (de) Klebstoffzusammensetzung und verfahren
NO933601D0 (no) Forbedret ligningsbasert treklebemiddel
FI951197A (fi) Mikrobisidiset koostumukset ja menetelmät
HU9400190D0 (en) Therapeutic compositions and methods
NO912773D0 (no) Antitumor-sammensetninger og fremgangsmaater for behandling
DE69605094D1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
DE69024818D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
ITMI931125A0 (it) Composizioni dentarie e di ricostruzione
DE69213415T2 (de) Elektroplattierungszusammensetzung und Verfahren
FI934360A (fi) Synergistiska antimalariakompositioner innehaollande benflumetol
IT1243911B (it) Composizioni per la terapia mucolitica
DE69115602D1 (de) Haarbehandlungszusammensetzung
NO923082D0 (no) Terapeutiske midler
IT8847888A0 (it) Composizioni erbicide sinergiche erelativo impiego di applicazione
KR930019375U (ko) 다리 교정 단련기
BR9006458A (pt) Combinacao fungicida de efeito sinergico e composicao fungicida
SE9200780D0 (sv) Composition for therapeutic use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time